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SUMMARY : We have studied NK activity against K562 cells and killer activity 
against NK-resistant Raji cells after administration of Methotrexate. Vinblastine, 
Adriamycine and Cis-platin (M-VAC) in patients with transitional cell carcinoma and found 
the appearance of strong lytic activity against K562 cells and Raji cells (lymphokine 
activated killer(LAK)-like activity) appeared 24.3 ± 6.5 days after the administration of 
first cycle of M-VAC and the lytic unit (LU) was 418.4 ± 177.4 (LU of pre-chemotherapy: 
88.6 ± 61.2). NK activity against K562 cells showed the same course as lymphokinne 
activated killer-like activity. There was a significant difference in activity of NK cells 
and LAK-like cells between pre-chemotherapy and maximum. NK cells and LAK-like 
cells activities after second or third cycle of M-VAC showed the same course as those 
of first cycle of M-CAC. Lymphocyte count decreased temporarily and increased during 
maximal activities of NK cells and LAK-like cells in each cycle of M-VAC therapy. 
However, maximal peak of lymphocyte count delayed in comparison with that of maximal 
activities of NK cells and LAK-like cells. Lymphokines, such as IL-2 may play a role 
to generate these enhanced NK activity and LAK-like activity. The data presented in 
this report suggests that the nature, dose, and timing of chemotherapeutic agent should 
be considered from the point of immunological mechanism.
       INTRODUCTION 
 Most anticancer drugs have immunosup-
pressive capabilities, and the immunosuppress-
ive action can be detected in various experimen-
tal systems. However, there are not so many 
investigations of cytotoxicity in peripheral blood 
lymphocytes (PBL) after cancer chemotherapy. 
We have studied the natural cell-mediated 
cytotoxicity of patients with carcinoma after 
cancer chemotherapy and found the strong 
natural cell-mediated cytotoxicity against NK-
resistant target cell after administration of 
Methotrexate, Vinblastine, Adriamycin and
Cis-platin (M-VAC)'). We have further inves-
tigated the natural cell-mediated cytotoxicity in 
patients with urinary bladder carcinoma or 
pyeloureteral carcinoma, and the relation bet-
ween lymphokine activated killer (LAK)-like 
activity and natural killer (NK) activity or these 
cytotoxicities and lymphocyte count.
    MATERIAL AND METHOD 
 Patients : Between January 1986 and July 1990, 
10 patients with transitional cell carcinoma of 
the bladder (6) and pyeloureter (4) were sub-
jected to this study. 
 Chemotherapy : Our chemotherapy consisted
of 30 Mg/ M2 methotrexate on day 1, and 3 mg/ 
m2 vinblastine, 30 mg/m' adriamycine and 70 
Mg/M2 cisplatinum administered on day 2, with 
the cycle repeating every 28 days'), Cis-platinum 
was administered after appropriate hydration 
as 1-hour infusion followed by routine post-
hydration fluid. Methotrexate and vinblastin 
were not administered on days 15 and 22 in all 
10 patients as the white blood cell count was 
less than 2000 per mm3. Seven patients received 
3 cycles of therapy. 
 Effector cells : PBL were isolated as effector 
cells from the heparin-treated blood of patients 
by separation on Ficoll-Hypaque gradients. 
Adherent cells were removed by 1 hour, 37'C 
incubation on plastic dishes precoated with 
autologus plasma. 
 Target cells : The cell line used in this study 
included human B cell lymphoma Raji cells and 
erythroleukemia K562 cells. Those cell lines 
were maintained in RPMI 1640, supplemented 
with 10% fetal calf serum. These cell lines were 
also monitored regularly for contamination and 
were found to be mycoplasma-free. 
 Cytotoxic Assay: A cytotoxicity assay was 
performed by 18 hours 51Cr-release assay. Per-
cent specific lysis was determined by using the 
formula. 
    lysis - cpm test - cpm medium x 100 
            cpm max - cpm medium 
Counts per minute (cpm) max was determined 
by counting an aliquot of resuspended target 
cells, cpm medium was determined in wells 
containing targets only with no effectors added. 
All experiments were done in triplicate in 
V-shaped 96 well microplate (Nunc, Denmark)
 Lytic units were calculated from cytotoxic 
titration curves. One LU was defined as the 
number of effector cells required to cause 20% 
lysis of 5 x 103 target cells. The data ware 
presented as LU/107 effector cells. 
 Statistical analysis : Statistical analysis was 
done by Wilcoxon signed-rank test. 
          RESULTR 
1) Characteristics of patients 
 The characteristics of evaluable patients are 
shown on Table 1. Among 10 patients, 9 were 
men and one was a woman, between 38 and 67 
years of age (mean age 59.3 years). With regard 
to performance status there were 7 patients with 
grade 0 and 3 with grade 2. 
2) NK and LAK-like activity 
 NK activity and LAK-like activity temporarily 
decreased after the administration of M-VAC 
in every cycle. The minimal activities of NK 
cells and LAK-like cells after the first cycle of 
M-VAC therapy were 264.1 ± 419.9 LU (pre-
chemotherapy: 613.6 ± 432.9 LU) and 21.9 ± 27.8 
LU (per-chemoterapy : 88.6 ± 61.2 LU) respec-
tively. These activities increased gradually from 
the nadir and maximal activities of NK cells and 
LAK-like cells after the administration in first 
cycle of M-VAC therapy were 970.6 ± 567.4 LU 
and 418.4 ± 177.4 LU respectively. Maximal 
activities of NK cells and LAK-like cells after 
chemotherapy express much higher activities 
than that of pre-chemotherapy level (Fig. 1, 2). 
There was a significant difference in activities 
of NK cells and LAK-like cells between pre-
chemotherapy and maximum. Activities of NK 
cells and LAK-like cells after second or third
               Table 1. Patient characteristics 
No. Case Sex Age P. S. Primary lesion Stage Grade 
 1 T. M. M 63 0 Bladder pT3b 3 
 2 S. K. M 65 2 Bladder pT4 3 
 3 M. N. M 67 0 Bladder pT2 3 
 4 H. F. F 38 0 Renal Pelvis pT2 2 
 5 K. E. M 67 0 Bladder pT2 3 
 6 H. M. M 46 0 Bladder T4 2 
 7 N. S. M 65 0 Ureter pT2 3 
 8 S. K. M 58 2 Ureter pT3b 2 
 9 M. H. M 63 2 Renal Pelvis pT3b 2 
10 S. T. M 61 0 Bladder pT3a 3
Fig. 4. The day of maximum NK Cell activity, 
      LAK-like cell activity and lymphocyte count 
      after administration of M-VAC.
Fig. 1. NK cell activity against K562 cells after 
      administration of M-VAC. C_totoxic ac-
       tivity was assayed by 18 hour 51Cr-release
       assay. LU was calculated from cytotoxic 
       titration curves of 51Cr-release assay.
Fig. 5. Lymphocyte count after administration of 
      M-VAC
Fig. 2. LAK-like cell activity against NK-resistant 
      Rail cells after administration of M-VAC. 
      Cytotoxic activity was assayed by 18 hour 
        51Cr -release assay .
Fig. 3. The day of minimum NK cell activity, 
      LAK-like cell activity and lymphocyte count 
      after administration of M-VAC.
cycle of M-VAC therapy showed the same 
course as those after the first cycle of M-VAC 
therapy. 
 Minimal activities of NK cells and LAK-like 
cells developed 7.7 ± 2.9 days and 8.4 ± 2.8 days 
respectively after the administration of first 
cycle of M-VAC therapy (Fig. 3). Maximal ac-
tivities of NK and LAK-like cells appeared 21.5 
± 6.5 days and 24.3 ± 6.5 days respectively after 
the administration of first cycle of M-VAC 
therapy. There were no significant difference 
in the day of appearance of minimal and 
maximal activities between NK and LAK-like 
activity, although the response to recover of NK 
activity was slightly earlier than LAK-like 
activity in the mean time. (Fig. 4) 
3) Lymphocyte count during chemotherapy of
M-VAC 
 Fig. 5 shows lymphocyte count during 
chemotherapy of M-VAC. After M-VAC therapy 
lymphocyte count decreased significantly during 
minimal activity of NK cells or LAK-like cells, 
but later it increased significantly during 
maximal activity of NK cells or LAK-like cells 
in each cycle of M-VAC therapy than that of 
pre-chemotherapy level. However, the maximal 
peak of lymphocyte count delayed in com-
parison with that of maximal activities of NK 
cells or LAK-like cells.
         DISCUSSION 
 It is well known that normal PBL can exhibit 
a number of killer cell functions including NK 
cell activity, cytotoxic T lymphocytes and LAK 
cell activity. NI cells can lyse certain cancer 
cells without prior sensitization and they are 
considered to play a role in the defense against 
cancer development. LAK cells are generated 
by culture of normal lymphocytes with 
interleukin 2 (IL-2), without any additional 
antigenic stimulation. LAK cells lyse a wide 
spectrum of allogenic and syngenic tumor 
cells" '). 
 We found an appearance of very strong killer 
activity against NK-resistant target cells in PBL 
after administration of M-VAC'±. The target 
spectrum of this killer cell was wide, and 
monoclonal antibody and complement treat-
ment revealed that effecter cells express CD8 
and SL-1 phenotypes weakly, but do not express 
CM, OOCD5, CD16, Leu-7, OKM1. These results 
suggest that effector cells are LAK-like. This 
strong killing activity against NK-resistant 
target cells was also induced by a combination 
chemotherapy with Cis-platinum, Etoposide and 
Bleomycin for testicular tumor patients. We 
think that this LAK-like cell induction is not 
due to specific drug actions but due to some 
common phenomenon such as a regeneration 
of myelosupression among these chemothera-
peutic agents. Indeed, our result showed that 
initially lymphocyte count decreased signifi-
cantly during minimal activity of NK cells or 
LAK-like cells after M-VAC therapy, but later 
it increased significantly during maximal 
activity of NK cells or LAK-like cells than that
of pre-chemotherapy level. The peak of lym-
phocyte count delayed in comparison with that 
of maximal activity of NK cells or LAK-like cells. 
That is, maximal activity of NK cells or 
LAK-like cells appeared during the rapid 
recovery of the number of lymphocytes. 
Hematopoietic progenitor cell colonies are 
known to be activated into LAK cells5' 6), and 
lymphokine such as IL-2 may play a role to 
generate enhanced NK activity and LAK-like 
activity. It is reported that after administration 
of a sublethal dose of cyclophophamide in the 
murine system, LAK cell, NK cell and CTL were 
abolished at once and the recovery was in the 
order of allogenic CTL, NK cell, LAK cell" 8'. 
However, a sublethal dose of cyclophosphamide 
did not induce LAK activity. In our results there 
was found no significant difference of recovery 
time between NK activity and LAK-like activity, 
althogh the response to recover of NK activity 
was slightly earlier than LAK-like activity in 
mean time. 
 The optimal drugs in patient with transition-
al cell carcinoma remain unknown. LAK-like 
activity seems to be higher in clinical responders 
than in clinical non-responders. This fact shows 
that LAK-like activity may be related to the 
tumor reduction. The present data suggest that 
the nature, dose and timing of chemothera-
peutic agents should be considered from the 
view point of immunological mechanism. The 
data also indicate usefulness of good timing of 
the additional chemotherapy or immuno-
therapy. If this killer activity could increase by 
administration of any biological response 
modifier, M-VAC therapy would be more ef-
fective.
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